We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Melatonin and Adiponectin in Hypertensive Kidney Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00498576
Recruitment Status : Completed
First Posted : July 10, 2007
Last Update Posted : June 30, 2009
Information provided by:

July 8, 2007
July 10, 2007
June 30, 2009
September 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00498576 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Melatonin and Adiponectin in Hypertensive Kidney Transplant
Not Provided

Recently we have shown that melatonin secretion is impaired in rats with metabolic syndrome. We have also demonstrated that exogenic melatonin supplementation can improve blood pressure profile in nondipper patients.

The aim of this study is to find whether there is a difference between melatonin secretion in hypertensive kidney recipients versus "normal" hypertensive patients. Secondly, to ask if there is any correlation between melatonin secretion and adiponectin levels.

Not Provided
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
group1- patients from the kidney transplant unit, sheba medical center group2- patients from hypertension unit,sheba medical center
  • Hypertension
  • Kidney Transplant
Not Provided
  • 1
    kidney transplant with hypertension
  • 2
    hypertensive patients with native kidneys
  • 3
    healthy controls
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  • hypertension
  • kidney transplantation ( group 1)
  • good renal function

Exclusion Criteria:

  • diabetes mellitus
  • cancer
  • renal failure
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
leibowitz avshalom, Sheba Medical Center
Sheba Medical Center
Not Provided
Principal Investigator: Avshalom Leibowitz, MD
Sheba Medical Center
June 2009